World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
39977
World Ranking
12027
National Ranking
15

Overview

Tadeusz Robak is affiliated with the Medical University of Lodz in Poland. Their research primarily focuses on the field of Medicine with a strong emphasis on several key subfields, including Genetics, Pathology and Forensic Medicine, Hematology, Immunology, and Oncology.

The main topics covered by their work include:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Acute Lymphoblastic Leukemia research
  • Protein Degradation and Inhibitors

Robak has published extensively, with a notable presence in various specialized venues. The most frequent publication venues include:

  • Blood
  • Acta Haematologica Polonica
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Leukemia & lymphoma/Leukemia and lymphoma

Among recent papers relevant to their field are:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, 2022, New England Journal of Medicine
  • Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial, 2022, The Lancet Oncology
  • Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia, 2022, Blood Advances

Collaborations have been a consistent feature of Robak's research career, with frequent coauthors including:

  • Paweł Robak
  • Paolo Ghia
  • Wojciech Jurczak
  • Jennifer R. Brown
  • Constantine S. Tam

Best Publications

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

    Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht

  • Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    John F. Seymour;Thomas J. Kipps;Barbara Eichhorst;Peter Hillmen

  • Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Robert Z. Orlowski;Arnon Nagler;Pieter Sonneveld;Joan Bladé

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

    Sean J. Whittaker;Marie-France Demierre;Ellen J. Kim;Alain H. Rook

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Peter Hillmen;Aleksander B. Skotnicki;Tadeusz Robak;Branimir Jaksic

  • Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

    Tadeusz Robak;Anna Dmoszynska;Philippe Solal-Céligny;Krzysztof Warzocha

  • Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

    Bertrand Coiffier;Stéphane Lepretre;Lars Møller Pedersen;Ole Gadeberg

  • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

    Hagop M Kantarjian;Ricardo Pasquini;Nelson Hamerschlak;Philippe Rousselot

  • Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Jorge E. Cortes;Florian H. Heidel;Andrzej Hellmann;Walter Fiedler

  • Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Jan A. Burger;Paul M. Barr;Tadeusz Robak;Carolyn Owen

  • Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

    Tadeusz Robak;Huiqiang Huang;Jie Jin;Jun Zhu

  • Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

    Peter Hillmen;Tadeusz Robak;Ann Janssens;K Govind Babu

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

    John C Byrd;Peter Hillmen;Paolo Ghia;Arnon P Kater

  • Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Martin S. Tallman;Tadeusz Robak;Steven Coutre

  • First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

    Anton Hagenbeek;Ole Vestergaard Gadeberg;Peter Johnson;Lars Møller Pedersen

Frequent Co-Authors

Peter Hillmen
Peter Hillmen St James's University Hospital
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Steven Coutre
Steven Coutre Stanford University
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Jennifer R. Brown
Jennifer R. Brown Harvard University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Susan O'Brien
Susan O'Brien University of California, Irvine
Arnon Nagler
Arnon Nagler Sheba Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine or a related healthcare field, there are a range of online degrees and specialized certificates that can broaden your opportunities. For those interested in advanced nursing roles, pursuing the cheapest dnp program can be a cost-effective way to achieve leadership positions in nursing practice.

Pharmacists are always in demand, and you can begin your journey by exploring accredited online pharmd programs that offer flexibility and affordability for busy professionals. If you are more interested in the management and organization of health data, enrolling in an him degree online can open up roles in healthcare administration, data management, and compliance.

Additionally, for those seeking quick entry into the healthcare workforce, medical billing and coding online courses provide practical skills that can lead to remote or office-based positions. By exploring these diverse, affordable online options, you can find a pathway in healthcare that fits your interests and career goals.

Best Scientists Citing Tadeusz Robak

Trending Scientists